Jaguar Health (JAGX) EBITDA Margin (2015 - 2026)
Jaguar Health's (JAGX) quarterly EBITDA Margin came in at 50.23% in Q1 2026, up 47575.0% year-on-year from N/an in Q1 2025, and up 107.65% on a QoQ basis from 656.63% in Q4 2025.
Jaguar Health (JAGX) EBITDA Margin (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 12 years of EBITDA Margin data on file, last reported at 50.23% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 47575.0% year-over-year to 50.23% in Q1 2026; TTM through Mar 2026 was 88.96%, a 18837.0% increase from a year earlier, with the FY2025 full-year figure at 398.82%, down 13506.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 50.23%, up from 656.63% in the prior quarter.
- Over the last five years, EBITDA Margin for JAGX reached as high as 50.23% in Q1 2026 and fell as low as 58770.0% in Q1 2022.
- Historically, EBITDA Margin has averaged 6140.83% across 5 years, with a median of 312.37% in 2023.
- Across the five-year window, EBITDA Margin plunged 5804434 bps in 2022 and soared 3689222 bps in 2023, its largest moves.
- Year by year, EBITDA Margin stood at 19643.75% in 2022, then surged by 98 bps to 328.57% in 2023, then increased by 29 bps to 232.46% in 2024, then slumped by 182 bps to 656.63% in 2025, then jumped by 108 bps to 50.23% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 50.23% in Q1 2026, 656.63% in Q4 2025, and 234.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,782.24 Bn | 1,782.18 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.46 Bn | 468.66 Bn | 1.35 Bn | 16.51% |
| 4 | Vertex Pharmaceuticals | 123.84 Bn | 116.59 Bn | 2.59 Bn | 38.10% |
| 5 | Regeneron Pharmaceuticals | 71.69 Bn | 62.94 Bn | 3.31 Bn | 17.83% |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - | - |
| 7 | Argenx Se | 54.74 Bn | 49.55 Bn | 1.41 Bn | 31.68% |
| 8 | Alnylam Pharmaceuticals | 38.08 Bn | 35.07 Bn | 959.66 Mn | 23.02% |
| 9 | Revolution Medicines | 36.07 Bn | 36.07 Bn | - | - |
| 10 | Jaguar Health | 520,945.88 | -9.54 Mn | 19.11 Mn | 50.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.23% |
| Dec 31, 2025 | -656.63% |
| Sep 30, 2025 | -234.77% |
| Jun 30, 2025 | -268.78% |
| Mar 31, 2025 | -425.52% |
| Dec 31, 2024 | -232.46% |
| Sep 30, 2024 | -233.66% |
| Jun 30, 2024 | -264.50% |
| Mar 31, 2024 | -349.43% |
| Dec 31, 2023 | -328.57% |
| Sep 30, 2023 | -312.37% |
| Jun 30, 2023 | -308.41% |
| Mar 31, 2023 | -21,877.78% |
| Dec 31, 2022 | -19,643.75% |
| Sep 30, 2022 | -315.86% |
| Jun 30, 2022 | -221.81% |
| Mar 31, 2022 | -58,770.00% |
| Dec 31, 2021 | -520.29% |
| Sep 30, 2021 | -1,549.43% |
| Jun 30, 2021 | -3,055.41% |